Han, Z., Sun, X., Jiang, G., & Du, X. (2016). Thalidomide for control delayed vomiting in cancer patients receiving chemotherapy. Journal of the College of Physicians and Surgeons—Pakistan, 26, 900–903. Retrieved from https://www.jcpsp.pk/archive/2016/Nov2016/07.pdf?
To assess the effect of thalidomide on delayed chemotherapy-induced vomiting
Patients were randomly allocated to treatment with thalidomide 25 mg four times per day and 50 mg at night beginning the day before chemotherapy. Both the intervention and treatment groups were given azasetron 10 mg IV 30 minutes before chemotherapy administration. Patients had received at least one cycle of chemotherapy prior to study inclusion.
PHASE OF CARE: Active antitumor treatment
Randomized, controlled trial
Delayed vomiting was fully or partly controlled in 88% of the treatment group and in 66% of the control group (p = 0.023).
Thalidomide might be helpful to control chemotherapy-induced nausea and vomiting.
Thalidomide might be useful for the control of chemotherapy-induced nausea and vomiting; however, additional well designed research is needed to determine the role of thalidomide as an option or adjunct to reduce nausea and vomiting.